Odanacatib, a selective cathepsin K inhibitor, increases areal bone mineral density (aBMD)
at the spine and hip of postmenopausal women. To gain additional insight into the effects on …

The osteoclast is an integral cell of bone resorption. Since osteolytic disorders hinge on the
function and dysfunction of the osteoclast, understanding osteoclast biology is fundamental …

The potent cathepsin K (CatK) inhibitor, Tanshinone IIA sulfonic sodium (T06), was tested for
its in vitro and in vivo antiresorptive activities. T06 binds in an ectosteric site of CatK remote …

The coupling between bone formation and resorption creates a therapeutic impasse in
osteoporosis: antiresorptive therapy halts bone loss, but also inhibits bone formation, and …

In mice and humans, the effect of genetic deficiency of cathepsin K (catK) is impaired bone
resorption, or osteopetrosis. Inhibition of catK is therefore a promising strategy for the …

Purpose Osteoporosis is a metabolic bone disease that commonly results in middle-aged
and elderly people following fractures. Odanacatib (ODN), a potential osteoporosis …

Introduction: The metabolic bone disease osteoporosis is a growing health and health-
economic problem worldwide. Bisphosphonates are the most widely used antiresorptive …

Cysteine cathepsins are lysosomal proteases with housekeeping as well as tissue-specific
functions. One of their specialized functions includes the degradation of extracellular matrix …

A sustained-release tablet (SRT) of ONO-5334 was compared to the immediate-release
tablet (IRT) dose, which demonstrated effects on bone mineral density (BMD) comparable to …

Cathepsin K inhibitors, such as ONO‐5334, are being developed for the treatment of
postmenopausal osteoporosis. However, their relative effects on bone resorption and …